Skip to main content

OliX Licenses AMD Drug to YuYu Pharma

Premium

NEW YORK (GenomeWeb) – Korean RNAi drug developer OliX Pharmaceuticals, formerly known as Biomolecular Therapeutics, announced today that it has licensed its siRNA-based age-related macular degeneration drug to YuYu Pharma.

The drug, called OLX301, comprises OliX's proprietary self-delivering siRNAs. Under the terms of the arrangement, YuYu will take over the drug's development, manufacturing, and commercialization. In exchange, OliX is eligible to receive milestone payments based on the drug's development and regulatory approval, as well as tiered royalties on product sales.

Additional terms of the deal were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.